290 related articles for article (PubMed ID: 8654369)
1. Molecular heterogeneity of RET loss of function in Hirschsprung's disease.
Carlomagno F; De Vita G; Berlingieri MT; de Franciscis V; Melillo RM; Colantuoni V; Kraus MH; Di Fiore PP; Fusco A; Santoro M
EMBO J; 1996 Jun; 15(11):2717-25. PubMed ID: 8654369
[TBL] [Abstract][Full Text] [Related]
2. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
3. RET activation by germline MEN2A and MEN2B mutations.
Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
[TBL] [Abstract][Full Text] [Related]
4. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease.
Pelet A; Geneste O; Edery P; Pasini A; Chappuis S; Atti T; Munnich A; Lenoir G; Lyonnet S; Billaud M
J Clin Invest; 1998 Mar; 101(6):1415-23. PubMed ID: 9502784
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations.
Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
Recent Results Cancer Res; 1998; 154():229-36. PubMed ID: 10027003
[TBL] [Abstract][Full Text] [Related]
6. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.
Geneste O; Bidaud C; De Vita G; Hofstra RM; Tartare-Deckert S; Buys CH; Lenoir GM; Santoro M; Billaud M
Hum Mol Genet; 1999 Oct; 8(11):1989-99. PubMed ID: 10484767
[TBL] [Abstract][Full Text] [Related]
7. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
[TBL] [Abstract][Full Text] [Related]
8. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
9. Mutations of the RET proto-oncogene in Hirschsprung's disease.
Edery P; Lyonnet S; Mulligan LM; Pelet A; Dow E; Abel L; Holder S; Nihoul-Fékété C; Ponder BA; Munnich A
Nature; 1994 Jan; 367(6461):378-80. PubMed ID: 8114939
[TBL] [Abstract][Full Text] [Related]
10. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.
Chappuis-Flament S; Pasini A; De Vita G; Ségouffin-Cariou C; Fusco A; Attié T; Lenoir GM; Santoro M; Billaud M
Oncogene; 1998 Dec; 17(22):2851-61. PubMed ID: 9879991
[TBL] [Abstract][Full Text] [Related]
11. A mutation in the RET proto-oncogene in Hirschsprung's disease affects the tyrosine kinase activity associated with multiple endocrine neoplasia type 2A and 2B.
Cosma MP; Panariello L; Quadro L; Dathan NA; Fattoruso O; Colantuoni V
Biochem J; 1996 Mar; 314 ( Pt 2)(Pt 2):397-400. PubMed ID: 8670046
[TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease.
Angrist M; Bolk S; Thiel B; Puffenberger EG; Hofstra RM; Buys CH; Cass DT; Chakravarti A
Hum Mol Genet; 1995 May; 4(5):821-30. PubMed ID: 7633441
[TBL] [Abstract][Full Text] [Related]
13. Oncological implications of RET gene mutations in Hirschsprung's disease.
Sijmons RH; Hofstra RM; Wijburg FA; Links TP; Zwierstra RP; Vermey A; Aronson DC; Tan-Sindhunata G; Brouwers-Smalbraak GJ; Maas SM; Buys CH
Gut; 1998 Oct; 43(4):542-7. PubMed ID: 9824583
[TBL] [Abstract][Full Text] [Related]
14. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.
Carlomagno F; Salvatore G; Cirafici AM; De Vita G; Melillo RM; de Franciscis V; Billaud M; Fusco A; Santoro M
Cancer Res; 1997 Feb; 57(3):391-5. PubMed ID: 9012462
[TBL] [Abstract][Full Text] [Related]
15. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.
Santoro M; Carlomagno F; Romano A; Bottaro DP; Dathan NA; Grieco M; Fusco A; Vecchio G; Matoskova B; Kraus MH
Science; 1995 Jan; 267(5196):381-3. PubMed ID: 7824936
[TBL] [Abstract][Full Text] [Related]
16. Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung's disease.
Nishikawa M; Murakumo Y; Imai T; Kawai K; Nagaya M; Funahashi H; Nakao A; Takahashi M
Eur J Hum Genet; 2003 May; 11(5):364-8. PubMed ID: 12734540
[TBL] [Abstract][Full Text] [Related]
17. Signal transduction pathways activated by RET oncoproteins in PC12 pheochromocytoma cells.
Xing S; Furminger TL; Tong Q; Jhiang SM
J Biol Chem; 1998 Feb; 273(9):4909-14. PubMed ID: 9478934
[TBL] [Abstract][Full Text] [Related]
18. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease.
Romeo G; Ronchetto P; Luo Y; Barone V; Seri M; Ceccherini I; Pasini B; Bocciardi R; Lerone M; Kääriäinen H
Nature; 1994 Jan; 367(6461):377-8. PubMed ID: 8114938
[TBL] [Abstract][Full Text] [Related]
19. [From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma].
Hofstra RM; van der Luijt RB; Lips CJ
Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2217-21. PubMed ID: 11757244
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
